India's genetic wealth offers huge biotech potential, notably with optogenetics. Despite initiatives and funding, bureaucratic hurdles previously slowed progress. Recent regulatory reforms, like streamlined trials and single-window clearances, are positive. Yet, to fully leverage its data and compete globally, India needs further ease in clinical testing, better patent approvals, and incentivized IP creation. A critical balance between regulatory speed and safety is paramount for unlocking India's full biotech capabilities and global standing.